Patterson Companies (PDCO)
(Delayed Data from NSDQ)
$20.27 USD
-0.01 (-0.05%)
Updated Oct 8, 2024 03:59 PM ET
After-Market: $20.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.27 USD
-0.01 (-0.05%)
Updated Oct 8, 2024 03:59 PM ET
After-Market: $20.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Zacks News
NextGen (NXGN) Behavioral Health Suite to Address Mental Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to ease state reporting and enable the secure sharing of patient information across providers.
Thermo Fisher (TMO) Launches New Chromosomal Microarray
by Zacks Equity Research
Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.
Patterson Cos. (PDCO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Patterson Cos. (PDCO) closed the most recent trading day at $33.78, moving -0.65% from the previous trading session.
Here's Why You Should Invest in HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients
by Zacks Equity Research
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) successful integration of the recently-acquired business and raised guidance.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.
Is Patterson Companies (PDCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Patterson Cos. (PDCO) and Abcam PLC Sponsored ADR (ABCM) have performed compared to their sector so far this year.
Reasons to Retain West Pharmaceutical (WST) Stock for Now
by Zacks Equity Research
West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.
Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.
McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow
by Zacks Equity Research
McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.
TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant
by Zacks Equity Research
TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.
Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind
by Zacks Equity Research
Phibro (PAHC) input costs continue to be high as a result of sustained inflation.
Neogen (NEOG) Introduces New Genomic Data Management Tool
by Zacks Equity Research
Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.
Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) broad product line.
Thermo Fisher (TMO) Completes the CorEvitas Acquisition
by Zacks Equity Research
Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Patterson Cos. (PDCO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Patterson Cos. (PDCO) closed at $33.83 in the latest trading session, marking a -1.4% move from the prior day.